In the course of the administrative
proceedings, the appellant argued that the State Institute for Drug Control
(SÚKL) failed to proceed in accordance with Section 39c(5) of the Act on Public
Health Insurance by not increasing the reimbursement of products containing the
selected active substance to ensure full reimbursement.
This provision stipulates that if, during
the process of determining...
Are you interested in reading regular commentaries on decisions by Pharmeca a.s.? Feel free to contact us.
At Pharmeca, we help you navigate the complex landscape of pharmaceutical and medical device information. We also offer flexible services that can be tailored to your needs at any time.
Our market position and experience allow us to support you whenever you need expert guidance.
Our knowledge, your opportunity.
